不良研究所 today announced it has signed agreements with ModernaTX, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to support two innovative...
不良研究所 has joined Moderna鈥檚 mRNA Access program, which aims to accelerate innovation and enable new vaccines and medicines for emerging and neglected infectious diseases through...
RSS